BLCM News and Press, Bellicum Pharmaceuticals Inc. From 11/03/20

HOUSTON, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the closing of its underwritten offering of 1,040,000 shares of common stock, pre-funded warrants to purc...

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks fell on Friday, led by the megacap tech names, to wrap up the worst week since March as coronavirus cases surged, U.S. fiscal stimulus...

Gainers: BioLineRx (BLRX) +76%.Marine Petroleum Trust (MARPS) +65%.DASAN Zhone Solutions (DZSI) +25%.Air Industries (AIRI) +21%.Rogers (ROG) +20%.Acadia Healthcare (ACHC) +18%.Tricida (TCDA) +17%.Covanta Holding (CVA) +16%.MoneyGram International (MGI) +14%.Daseke (DSKE) +14%.Losers: ...

Gainers: BioLineRx BLRX +63%, Acadia Healthcare ACHC +19%, Tricida (TCDA) +14%, Cleveland BioLabs (CBLI) +12%, Equillium EQ +4%.Losers: Axovant Gene Therapies (AXGT) -39%, Bellicum Pharmaceuticals (BLCM) -38%, OPKO Health (OPK) -20%,...

Bellicum Pharmaceuticals (BLCM) -34% after slashing headcount by 79%.Axovant Gene Therapies (AXGT) -29% in reaction to delays in enrollment in Parkinson's study with gene therapy.MicroVision (MVIS) -20% on Q3 earnings results.Twitter (TWTR) -16%. on Q3 earni...

Bellicum Pharmaceuticals (BLCM) announced restructuring program, wherein it will focus on the clinical development of BPX-601 and BPX-603, pause the BCMA GoCAR-NK program, and discontinue discovery research and new product development. Staff will be reduced by 79%, from 68 to 14 employee...

Bellicum Pharmaceuticals (BLCM) priced its underwritten offering priced at-the-market under Nasdaq rules of 4.15M shares and accompanying warrants.Each share of common stock is being sold together with one warrant to purchase one share of common stock at a combined effective price of $6.025.O...

HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing of an underwritten offering priced at-the-market under Nasdaq rules of 4,149,378 shares of it...

HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced interim data from its BPX-601 dose-escalation clinical trial in patients with relapsed/refractory metasta...

HOUSTON, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that management will participate in two upcoming virtual conferences. Conference Details: ...